Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel therapies with chimeric antigen receptor (CAR)-transduced T cells (TCs) sparked new hope for patients with relapsed or refractory CD19-positive leukemia or lymphoma even after stem cell therapies.
|
27479233 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
|
23233573 |
2012 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results are the first to establish the clinical activity of a CD22-CAR in B-ALL, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
|
29155426 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
|
28515942 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity.
|
15507526 |
2005 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19<sup>-</sup> leukemia that aberrantly expressed the anti-CD19 CAR.
|
30275568 |
2018 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
|
30733273 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
|
30097433 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Administration of CD19-specific CAR-modified T cells that target B cell non-Hodgkin lymphomas and leukemia has been remarkably effective in recent clinical trials, energizing the field and stimulating new efforts to identify the critical parameters of CAR design and T cell engineering that are necessary for effective cancer therapy.
|
24338745 |
2014 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four hematological groups could be distinguished: (i) 13 cases of acute lymphoblastic leukemia (ALL) of B lineage, mostly CD19+; (ii) eight cases of biphenotypic leukemia: CD19+ (most often) ALL but with simultaneous or inducible expression of differentiation marker of monocytic lineage.
|
8426468 |
1993 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infusion of CD19-ENG T cells resulted in regression of leukemia or lymphoma in xenograft models and a survival advantage in comparison to control mice.
|
27255991 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use.
|
30622115 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such incongruity was also observed in t(4;11) patients in whom leukemia evaded CD19-directed therapy by undergoing myeloid-lineage switch.
|
27846391 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we compared CD19 bispecific T-cell engager (BiTE)-transferred T cells that had been transfected by RNA electroporation with CD19 CAR RNA-transferred T cells both in vitro and in an aggressive Nalm6 leukemia mouse model.
|
27258611 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
|
12393484 |
2003 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a preclinical validation using a model of CD33<sup>+</sup> AML, and generated iC9 CAR T-cells co-expressing a CAR targeting the AML-associated antigen CD33 and a selectable marker (ΔCD19).ΔCD19 selected (sel.) iC9-CAR.CD33 T-cells were effective in controlling leukemia growth in vitro, and could be partially eliminated (76%) using a chemical inducer of dimerization that activates iC9.
|
30539529 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In one case a bilineage leukemia with a POEM+/CD 19- and a POEM-/CD 19+ population could be identified by immunoelectron microscopical studies (IEM).
|
7920215 |
1994 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
|
19147788 |
2009 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
|
18829563 |
2008 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.
|
28453885 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-targeted CAR-T is an effective modality in treating refractory B-cell malignancies including leukemia and lymphoma.
|
28762313 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells.
|
23296936 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The engineered CD4(+) T cells and CD8(+) T cells both exhibited specific cytotoxicity against CD19(+) leukemia and lymphoma cell lines, as well as against CD19 transfectants, and produced high-levels of antigen-dependent Th1 (but not Th2) cytokines.
|
18227839 |
2008 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical use of genetically modified T-cell therapies has led to unprecedented response rates in leukemia and lymphoma patients treated with anti-CD19 chimeric antigen receptor (CAR)-T. Despite this clinical success, FDA-approved T-cell therapies are currently limited to B-cell malignancies, and challenges remain with managing cytokine-related toxicities.
|
30479831 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Challenging ΔCD19 selected inducible Caspase9-CAR.CD33 T-cells with programmed-death-ligand-1 enriched leukemia blasts resulted in significant killing like observed for the programmed-death-ligand-1 negative leukemic blasts fraction.
|
27907031 |
2016 |